In the ongoing exercise of TO 6 B, CLS has agreed on top down underwriting commitments with qualified investors. The underwriting commitments comprises a total of
The underwriting commitments constitute a so-called "top-down" or "top guarantee", which means that if TO 6 B is exercised to approximately 70 per cent, underwriting subscription is executed for the remaining 30 per cent up to a fully subscribed TO 6 B. The underwriting commitments is thus added to the existing subscription level for TO 6 B and is intended to ensure the last part of the subscription in the warrant exercise in the event that all TO 6 B are not exercised by existing holders. For the underwriting commitments, a cash compensation of fifteen (15) per cent of the underwritten amount is paid. Of the total underwritten amount, approximately
In the event that the underwriting commitments are activated, subscription of shares will take place through a directed share issue carried out after the exercise period for TO 6 B has ended. Subscription in such a directed share issue shall be made at the established price for TO 6 B and only to the extent TO 6 B has not been exercised by existing holders within the scope of the underwriting commitments (corresponding to a maximum of 70,000,000 B-shares in the Company). The Board of Directors will not decide on the directed share issue to use the underwriting commitment in case the Board of Directors does not consider it justifiable taking into account a customary issue cost.
Information brochures about the Company and the offer (in Swedish and English) and other material for investors are available on CLS, Sedermera Corporate Finance AB's, Redeye AB's and Nordic Issuing AB's respective websites (www.clinicallaser.se, www.sedermera.se, www.redeye.se, www.nordic-issuing.se). Complete terms and conditions and instructions for warrants of series TO 6 B are available on the Company's website.
For more information about the warrants of series TO 6 B, please contact:
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
Website: www.sedermera.se
Phone: +46 (0)8 545 013 30
E-mail: info@redeye.se
Website: www.redeye.se
For more information about CLS, please contact:
Dan J Mogren, CEO,
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
Website: www.clinicallaser.se
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
About CLS
For more information about CLS, please visit the Company's website: www.clinicallaser.se
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on
https://news.cision.com/cls/r/clinical-laserthermia-systems-ab-enters-into-top-down-underwriting-commitments-in-the-ongoing-exerci,c3921411
https://mb.cision.com/Main/11591/3921411/2579325.pdf
(c) 2024 Cision. All rights reserved., source